JP2025504374A - 二環式フタラジン－１（２ｈ）－オン誘導体および関連する使用法 - Google Patents
二環式フタラジン－１（２ｈ）－オン誘導体および関連する使用法 Download PDFInfo
- Publication number
- JP2025504374A JP2025504374A JP2024540866A JP2024540866A JP2025504374A JP 2025504374 A JP2025504374 A JP 2025504374A JP 2024540866 A JP2024540866 A JP 2024540866A JP 2024540866 A JP2024540866 A JP 2024540866A JP 2025504374 A JP2025504374 A JP 2025504374A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- cycloalkyl
- disease
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263297444P | 2022-01-07 | 2022-01-07 | |
| US63/297,444 | 2022-01-07 | ||
| PCT/US2023/010314 WO2023133271A1 (en) | 2022-01-07 | 2023-01-06 | Bicyclic phthalazin-1(2h)-one derivatives and related uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025504374A true JP2025504374A (ja) | 2025-02-12 |
| JP2025504374A5 JP2025504374A5 (https=) | 2025-12-18 |
| JPWO2023133271A5 JPWO2023133271A5 (https=) | 2025-12-18 |
Family
ID=85239129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540866A Pending JP2025504374A (ja) | 2022-01-07 | 2023-01-06 | 二環式フタラジン－１（２ｈ）－オン誘導体および関連する使用法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250066369A1 (https=) |
| EP (1) | EP4460505A1 (https=) |
| JP (1) | JP2025504374A (https=) |
| KR (1) | KR20240145992A (https=) |
| CN (1) | CN118922421A (https=) |
| AU (1) | AU2023205048A1 (https=) |
| CA (1) | CA3247232A1 (https=) |
| IL (1) | IL314035A (https=) |
| MX (1) | MX2024008477A (https=) |
| WO (1) | WO2023133271A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025153532A1 (en) * | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| RU2364597C1 (ru) * | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ |
| CN116194445A (zh) * | 2020-09-24 | 2023-05-30 | 詹森药业有限公司 | 新化合物 |
-
2023
- 2023-01-06 CN CN202380025701.8A patent/CN118922421A/zh active Pending
- 2023-01-06 WO PCT/US2023/010314 patent/WO2023133271A1/en not_active Ceased
- 2023-01-06 EP EP23705320.2A patent/EP4460505A1/en active Pending
- 2023-01-06 IL IL314035A patent/IL314035A/en unknown
- 2023-01-06 MX MX2024008477A patent/MX2024008477A/es unknown
- 2023-01-06 US US18/726,919 patent/US20250066369A1/en active Pending
- 2023-01-06 KR KR1020247026276A patent/KR20240145992A/ko active Pending
- 2023-01-06 AU AU2023205048A patent/AU2023205048A1/en active Pending
- 2023-01-06 CA CA3247232A patent/CA3247232A1/en active Pending
- 2023-01-06 JP JP2024540866A patent/JP2025504374A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3247232A1 (en) | 2023-07-13 |
| US20250066369A1 (en) | 2025-02-27 |
| IL314035A (en) | 2024-09-01 |
| WO2023133271A1 (en) | 2023-07-13 |
| CN118922421A (zh) | 2024-11-08 |
| KR20240145992A (ko) | 2024-10-07 |
| AU2023205048A1 (en) | 2024-07-18 |
| MX2024008477A (es) | 2024-08-30 |
| EP4460505A1 (en) | 2024-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7648828B2 (ja) | Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物 | |
| JP7328995B2 (ja) | Ｐｄ－ｌ１免疫調節剤としてのテトラヒドロ－イミダゾ［４，５－ｃ］ピリジン誘導体 | |
| JP2021506966A (ja) | Ｎｌｒｐ３インフラマソーム調節剤としてのスルホニル尿素誘導体 | |
| CN111406063B (zh) | 作为抗癌剂的环二核苷酸 | |
| JP7239497B2 (ja) | 化合物 | |
| TW201910306A (zh) | Nlrp3發炎體之選擇性抑制劑 | |
| CN111315749A (zh) | 新颖的二氢异噁唑化合物及其在治疗乙型肝炎中的用途 | |
| JP2021514982A (ja) | インドール−２−カルボニル化合物及びｂ型肝炎治療のためのそれらの使用 | |
| TW201811799A (zh) | 吡唑并嘧啶化合物及其用途 | |
| CN110831942A (zh) | 作为抗病毒药的稠合吲唑吡啶酮化合物 | |
| CN111433210A (zh) | 作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物 | |
| CN111566089A (zh) | Ire1小分子抑制剂 | |
| CN114728975A (zh) | 唑稠合的哒嗪-3(2h)-酮衍生物 | |
| JP2025522354A (ja) | 置換３，４－ジヒドロイソキノリン－１（２ｈ）－オン誘導体および関連する使用 | |
| CN107074805A (zh) | 用于治疗疾病的gls1抑制剂 | |
| CN105263923B (zh) | 嘧啶化合物及它们作为γ分泌酶调节剂的用途 | |
| TW201835079A (zh) | ６－吡唑－［１，２，４］三唑並［４，３－α］吡啶－３－醯胺類衍生物、其製備方法及其在醫藥上的應用 | |
| TW202425965A (zh) | 縮環化合物及含有其之醫藥 | |
| JP2025504374A (ja) | 二環式フタラジン－１（２ｈ）－オン誘導体および関連する使用法 | |
| WO2025218735A1 (zh) | 五环类衍生物抑制剂、其制备方法和应用 | |
| TW202525792A (zh) | 經取代之側氧異吲哚啉基哌啶－２，６－二酮化合物 | |
| WO2023274396A1 (zh) | 苯并氮杂环类化合物及其在药物中的应用 | |
| CN112759541B (zh) | 类吲哚衍生物及其用途 | |
| HK40117941A (zh) | 包含抗癌剂和对前列腺素e2受体具有抑制活性的新化合物的用於治疗癌症的药物组合物 | |
| HK40105393A (zh) | Sting(干扰素基因刺激剂)的调节剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240807 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251210 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251210 |